valsartan (diovan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
There is no information in the literature about pharmacological and biological application of definite isomer of valsatran, R – form (also known as VALSARTAN, D- or CGP-49309). However there were found, that in the tablets of valsartan, which are used to treat high blood pressure and to heart failure, the R-enantiomer was an impurity.   NCATS

Chemistry

  • SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=NN3)[C@@H](C(C)C)C(O)=O
  • InChIKey: ACWBQPMHZXGDFX-QFIPXVFZSA-N
  • Mol. Mass: 435.5188
  • ALogP: 4.16
  • ChEMBL Molecule:
    valsartan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$0.1376 - $0.3259

United States

$0.2436 - $10.5126
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( nebivolol (bystolic), valsartan (diovan) )
|
( valsartan (diovan), hydrochlorothiazide (esidrix) )
|
( valsartan (diovan), sacubitril (Entresto) - other names: sacubitril and valsartan, sacubitril/valsartan 49/51mg/tab )
|
( amlodipine (norvasc), valsartan (diovan) )
|
( amlodipine (norvasc), valsartan (diovan), hydrochlorothiazide (esidrix) )
|
( valsartan (diovan), aliskiren (tekturna) )

Alternative names

amlodipine (as besylate) / valsartan | amlodipine besilate / valsartan | amlodipine besylate / valsartan / hydrochlorothiazide | amlodipine mixture with valsartan | amlodipine / valsartan | amlodipine / valsartan / hydrochlorothiazide | angiotensin | cardopan | cgp 48933 | cgp-48933 | diovan | exforge | n-pentanoyl-n-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-l-valine | n-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)-n-valeryl-l-valine | orosartan | sacubitril / valsartan | (s)-n-valeryl-n-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine | valsartan | valsartanin

Organizations (314)

Research & Development (280)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (36)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (123)

Approved Indications (6)


 

Diabetes Mellitus

Heart Failure

Hypertension

Myocardial Infarction

Stroke

Ventricular Dysfunction, Left

Experimental Indications - Clinical Trial Phases 1-4 (123)


 

Acute Coronary Syndrome (Phase 2)

Administration, Oral (Phase 1)

Aging (Phase 2)

Albuminuria (Phase 4)

Angiotensin II Type 1 Receptor Blockers (Phase 4)

Angiotensin Receptor Antagonists (Phase 4)

Antihypertensive Agents (Phase 4)

Aortic Aneurysm, Abdominal (Phase 4)

Aortic Valve Insufficiency (Phase 2)

Aortic Valve Stenosis (Phase 2/Phase 3)

Arrhythmias, Cardiac (Phase 2)

Arthritis (Phase 1/Phase 2)

Atherosclerosis (Phase 3)

Atrial Fibrillation (Phase 4)

Atrial Remodeling (Phase 2)

Blood Pressure (Phase 4)

Breast Diseases (Phase 4)

Breast Neoplasms (Phase 4)

Cardiomyopathy, Dilated (Phase 4)

Cardiomyopathy, Hypertrophic (Phase 2/Phase 3)

Cardiotoxicity (Phase 4)

Cardiovascular Diseases (Phase 4)

Carotid Artery Diseases (Phase 2)

Chagas Cardiomyopathy (Phase 3)

Chagas Disease (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Cognitive Dysfunction (Phase 3)

Connective Tissue Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 3)

COVID-19 (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Angiopathies (Phase 4)

Diabetic Nephropathies (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drugs, Investigational (Phase 4)

Dyslipidemias (Phase 4)

Endomyocardial Fibrosis (Phase 2)

Endothelial Cells (Phase 3)

Energy Metabolism (Phase 2)

Erectile Dysfunction (Phase 4)

Essential Hypertension (Phase 4)

Exercise (Phase 4)

Glomerulonephritis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Glomerulonephritis, Membranous (Phase 4)

Glomerulosclerosis, Focal Segmental (Phase 4)

Glucose Intolerance (Phase 4)

Hamartoma (Phase 4)

Healthy Volunteers (Phase 4)

Heart Defects, Congenital (Phase 2/Phase 3)

Heart Diseases (Phase 4)

Heart Failure ()

Heart Failure, Diastolic (Phase 4)

Heart Failure, Systolic (Phase 4)

Heart Valve Prosthesis Implantation (Phase 2/Phase 3)

Hemodialysis, Home (Phase 4)

HIV (Phase 2)

HIV Infections (Phase 3)

Hypercholesterolemia (Phase 4)

Hyperkalemia (Phase 3)

Hyperlipidemias (Phase 3)

Hypertension ()

Hypertension, Pulmonary (Phase 3)

Hypertrophy, Left Ventricular (Phase 4)

Hypotension (Phase 4)

Hypoxia (Phase 4)

Insulin Resistance (Phase 2)

Ischemic Stroke (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 4)

Lung Diseases (Phase 2)

Lymphoma, Non-Hodgkin (Phase 4)

Magnetic Resonance Imaging (Phase 1)

Metabolic Diseases (Phase 2)

Metabolic Syndrome (Phase 4)

Metabolism (Phase 2)

Mitral Valve (Phase 4)

Mitral Valve Insufficiency (Phase 4)

Molecular Mechanisms of Pharmacological Action (Phase 4)

Myocardial Infarction ()

Myocardial Ischemia (Phase 4)

Myocardium (Phase 4)

Myositis (Phase 2)

Natriuretic Peptides (Phase 2/Phase 3)

Neoplasms (Phase 4)

Neoplasms, Second Primary (Phase 4)

Nephritis, Hereditary (Phase 2)

Nephrotic Syndrome (Phase 1)

Non-ST Elevated Myocardial Infarction (Phase 3)

Obesity (Phase 4)

Osteoporosis (Phase 4)

Oxidative Stress (Phase 3)

Peripheral Arterial Disease (Phase 2)

Pharmacokinetics (Phase 1)

Prediabetic State (Phase 4)

Prehypertension (Phase 4)

Prostheses and Implants (Phase 4)

Proteinuria (Phase 4)

Pulmonary Arterial Hypertension (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Purpura (Early Phase 1)

Renal Dialysis (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Renin-Angiotensin System (Phase 2/Phase 3)

Respiratory Distress Syndrome (Phase 4)

Sarcopenia (Phase 2)

SARS-CoV-2 (Phase 4)

Sclerosis (Phase 4)

Severe Acute Respiratory Syndrome (Phase 4)

Shock, Cardiogenic (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Sleep Apnea Syndromes (Phase 4)

ST Elevation Myocardial Infarction (Phase 3)

Stroke (Phase 4)

Transcatheter Aortic Valve Replacement (Phase 2/Phase 3)

Valsartan (Phase 2/Phase 3)

Ventricular Dysfunction, Left (Phase 4)

Ventricular Dysfunction, Right (Phase 2)

Ventricular Remodeling (Phase 4)

Vitamin D Deficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 377
  • # of Trial Organizations: 280

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue